PMID- 20651360
OWN - NLM
STAT- MEDLINE
DCOM- 20100824
LR  - 20151119
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 30
IP  - 6
DP  - 2010 Jun
TI  - Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute 
      lymphoblastic and myeloblastic leukaemia.
PG  - 2119-24
AB  - The proteasome inhibitor, bortezomib, is known to be effective in the therapy of 
      various neoplasms. The objective of this study was the analysis of the ex vivo 
      activity of bortezomib in paediatric acute lymphoblastic leukaemia (ALL), in 
      comparison to paediatric acute myeloid leukaemia (AML). A total of 159 patients 
      entered the study, including 106 ALL (including 86 precursor-B-cell ALL, and 20 
      T-cell ALL) and 53 AML children. The ex vivo sensitivity to bortezomib and 16 
      other drugs was studied by MTT assay. Paediatric AML samples were more resistant 
      than paediatric ALL samples to most of the tested drugs, except for cytarabine 
      and thioguanine. With respect to immunophenotype, ex vivo drug resistance in 
      T-cell ALL (T-ALL) was higher for most of the drugs. No differences in drug 
      resistance between T-ALL and common/pre-B-cell-ALL were found for daunorubicin, 
      mitoxantrone and 6-thioguanine. Bortezomib was the only compound which was more 
      active in T-ALL than in common/pre-B-ALL paediatric samples. In conclusion, 
      bortezomib had good ex vivo activity in paediatric T-ALL samples.
FAU - Szczepanek, Joanna
AU  - Szczepanek J
AD  - Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus 
      Copernicus University, ul. Curie-Sklodowskiej 9, 85-094 Bydgoszcz, Poland.
FAU - Pogorzala, Monika
AU  - Pogorzala M
FAU - Konatkowska, Benigna
AU  - Konatkowska B
FAU - Juraszewska, Edyta
AU  - Juraszewska E
FAU - Badowska, Wanda
AU  - Badowska W
FAU - Olejnik, Igor
AU  - Olejnik I
FAU - Kuzmicz, Marta
AU  - Kuzmicz M
FAU - Stanczak, Elzbieta
AU  - Stanczak E
FAU - Malinowska, Iwona
AU  - Malinowska I
FAU - Stefaniak, Jolanta
AU  - Stefaniak J
FAU - Sobol, Grazyna
AU  - Sobol G
FAU - Szczepanski, Tomasz
AU  - Szczepanski T
FAU - Czyzewski, Krzysztof
AU  - Czyzewski K
FAU - Wysocki, Mariusz
AU  - Wysocki M
FAU - Styczynski, Jan
AU  - Styczynski J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Boronic Acids)
RN  - 0 (Pyrazines)
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Agents/*therapeutic use
MH  - Boronic Acids/*therapeutic use
MH  - Bortezomib
MH  - Child
MH  - Child, Preschool
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Infant
MH  - Leukemia, Myeloid, Acute/*drug therapy
MH  - Male
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
MH  - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
MH  - Pyrazines/*therapeutic use
EDAT- 2010/07/24 06:00
MHDA- 2010/08/25 06:00
CRDT- 2010/07/24 06:00
PHST- 2010/07/24 06:00 [entrez]
PHST- 2010/07/24 06:00 [pubmed]
PHST- 2010/08/25 06:00 [medline]
AID - 30/6/2119 [pii]
PST - ppublish
SO  - Anticancer Res. 2010 Jun;30(6):2119-24.